US EditionWeight loss drugs could slash hospital risk for heart failure patients: Study
- Weight-Loss injections Mounjaro and Wegovy can reduce the risk of death for heart failure patients by half, according to a study presented at a heart conference in Madrid.
- The study involved 90,000 U.S. patients with heart failure, obesity, and type 2 diabetes.
- Dr. Aguiar stated that there is a benefit in using semaglutide or tirzepatide to reduce hospitalization risk or all-cause mortality.
- Dr. Desai emphasized the need for randomized outcome trials before changing treatment practices regarding these therapies.
Insights by Ground AI
Does this summary seem wrong?
11 Articles
11 Articles
Evening Standard+2 Reposted by 2 other sources
Weight loss drugs could slash hospital risk for heart failure patients
Heart failure happens when the heart is unable to pump blood around the body properly.
·London, United Kingdom
Read Full Article
A large study shows that GLP-1 drugs, such as semaglutide and tirzepatide, reduce the risk of hospitalization or premature death in heart patients by up to 58%.
Coverage Details
Total News Sources11
Leaning Left3Leaning Right3Center1Last UpdatedBias Distribution43% Left, 43% Right
Bias Distribution
- 43% of the sources lean Left, 43% of the sources lean Right
43% Right
L 43%
14%
R 43%
Factuality
To view factuality data please Upgrade to Premium
